Drug profile · INN
emapalumab-lzsg
GAMIFANT
emapalumab-lzsg (GAMIFANT) is a interferon gamma inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — emapalumab-lzsg
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
emapalumab-lzsg (GAMIFANT) is a interferon gamma inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interferon gamma inhibitor
Primary target: Interferon gamma
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is emapalumab-lzsg?
emapalumab-lzsg (GAMIFANT) is a interferon gamma inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for emapalumab-lzsg?
GAMIFANT is a marketed brand name for emapalumab-lzsg. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of emapalumab-lzsg?
emapalumab-lzsg has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.